Mvundura Mercy, Lydon Patrick, Gueye Abdoulaye, Diaw Ibnou Khadim, Landoh Dadja Essoya, Toi Bafei, Kahn Anna-Lea, Kristensen Debra
Devices and Tools Program, PATH, Seattle, USA.
Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
Pan Afr Med J. 2017 Jun 23;27(Suppl 3):27. doi: 10.11604/pamj.supp.2017.27.3.12087. eCollection 2017.
A recent innovation in support of the final segment of the immunization supply chain is licensing certain vaccines for use in a controlled temperature chain (CTC), which allows excursions into ambient temperatures up to 40°C for a specific number of days immediately prior to administration. However, limited evidence exists on CTC economics to inform investments for labeling other eligible vaccines for CTC use. Using data collected during a MenAfriVac™ campaign in Togo, we estimated economic costs for vaccine logistics when using the CTC approach compared to full cold chain logistics (CCL) approach.
We conducted the study in Togo's Central Region, where two districts were using the CTC approach and two relied on a fullCCL approach during the MenAfriVac™ campaign. Data to estimate vaccine logistics costs were obtained from primary data collected using costing questionnaires and from financial cost data from campaign microplans. Costs are presented in 2014 US dollars.
Average logistics costs per dose were estimated at $0.026±0.032 for facilities using a CTC and $0.029±0.054 for facilities using the fullCCL approach, but the two estimates were not statistically different. However, if the facilities without refrigerators had not used a CTC but had received daily deliveries of vaccines, the average cost per dose would have increased to $0.063 (range $0.007 to $0.33), with larger logistics cost increases occurring for facilities that were far from the district.
Using the CTC approach can reduce logistics costs for remote facilities without cold chain infrastructure, which is where CTC is designed to reduce logistical challenges of vaccine distribution.
支持免疫供应链最后环节的一项最新创新是为某些疫苗发放许可,使其可在可控温度链(CTC)中使用,这允许在接种前特定天数内疫苗可暴露于高达40°C的环境温度下。然而,关于可控温度链的经济学证据有限,无法为将其他合格疫苗标记为可用于可控温度链的投资提供参考。利用在多哥开展的脑膜炎疫苗项目(MenAfriVac™)期间收集的数据,我们估计了与全程冷链物流(CCL)方法相比,采用可控温度链方法时疫苗物流的经济成本。
我们在多哥中部地区开展了这项研究,在脑膜炎疫苗项目期间,该地区有两个区采用可控温度链方法,另外两个区依赖全程冷链物流方法。用于估计疫苗物流成本的数据来自使用成本核算问卷收集的原始数据以及项目微观计划中的财务成本数据。成本以2014年美元表示。
采用可控温度链的设施每剂疫苗的平均物流成本估计为0.026±0.032美元,采用全程冷链物流方法的设施为0.029±0.054美元,但这两个估计值在统计学上无差异。然而,如果没有冰箱的设施未采用可控温度链方法而是每天接收疫苗配送,每剂疫苗的平均成本将增至0.063美元(范围为0.007美元至0.33美元),距离该区较远的设施物流成本增加幅度更大。
采用可控温度链方法可降低没有冷链基础设施的偏远设施的物流成本,而可控温度链的设计目的正是减少疫苗配送中的物流挑战。